HC Wainwright Reaffirms “Buy” Rating for AnaptysBio (NASDAQ:ANAB)

AnaptysBio (NASDAQ:ANAB)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report issued on Thursday, Benzinga reports. They presently have a $55.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 147.97% from the stock’s previous close.

Several other equities research analysts have also issued reports on the stock. Wedbush restated an “outperform” rating and issued a $42.00 target price on shares of AnaptysBio in a report on Thursday, September 26th. Guggenheim raised their price objective on shares of AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. JPMorgan Chase & Co. boosted their target price on AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. UBS Group increased their price target on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a report on Wednesday. Finally, Truist Financial boosted their price objective on AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $55.73.

AnaptysBio Price Performance

Shares of NASDAQ ANAB opened at $22.18 on Thursday. AnaptysBio has a 1-year low of $13.36 and a 1-year high of $41.31. The business’s 50 day moving average is $34.92 and its two-hundred day moving average is $29.88. The stock has a market capitalization of $605.94 million, a P/E ratio of -3.61 and a beta of -0.29.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.82). The company had revenue of $10.97 million for the quarter, compared to the consensus estimate of $25.85 million. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. As a group, equities research analysts anticipate that AnaptysBio will post -6.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Ecor1 Capital, Llc purchased 273,972 shares of the business’s stock in a transaction dated Wednesday, August 14th. The shares were purchased at an average price of $36.50 per share, for a total transaction of $9,999,978.00. Following the completion of the purchase, the insider now owns 7,794,996 shares in the company, valued at approximately $284,517,354. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In other news, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the sale, the insider now owns 15,398 shares of the company’s stock, valued at approximately $595,440.66. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Ecor1 Capital, Llc acquired 273,972 shares of the company’s stock in a transaction dated Wednesday, August 14th. The shares were acquired at an average price of $36.50 per share, for a total transaction of $9,999,978.00. Following the completion of the purchase, the insider now owns 7,794,996 shares of the company’s stock, valued at approximately $284,517,354. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 22,440 shares of company stock worth $892,936. 33.70% of the stock is currently owned by company insiders.

Institutional Trading of AnaptysBio

A number of hedge funds have recently bought and sold shares of ANAB. Rhumbline Advisers raised its position in shares of AnaptysBio by 1.8% in the 2nd quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company’s stock worth $745,000 after acquiring an additional 525 shares in the last quarter. Algert Global LLC grew its stake in AnaptysBio by 11.8% in the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock valued at $255,000 after purchasing an additional 1,078 shares during the last quarter. nVerses Capital LLC raised its holdings in AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 1,400 shares in the last quarter. Values First Advisors Inc. purchased a new stake in shares of AnaptysBio during the third quarter valued at about $49,000. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of AnaptysBio in the 1st quarter valued at about $38,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.